Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining.

Area of Science:

• Malariology
• Drug Discovery
• Genomics

Background:

• Traditional antimalarial drug discovery relies on phenotypic screens, which are resource-intensive and may miss novel targets.
• Investigating drug targets retroactively limits the scope of potential antimalarial compounds.
• Existing methods may not identify targets outside current compound libraries or assay conditions.

Purpose of the Study:

• To systematically identify and prioritize novel drug targets in the malaria parasite Plasmodium falciparum.
• To develop a generalizable framework for evaluating potential drug targets in pathogens.
• To discover new targets for small molecule inhibitors against malaria.

Main Methods:

• Leveraged advances in protein structure prediction and data mining to assess the Plasmodium falciparum genome.
• Identified 867 candidate targets with evidence of small molecule binding and blood-stage essentiality.
• Applied expert review and rubric-based scoring to prioritize candidates based on selectivity, structural data, and assay developability.

Main Results:

• Identified 867 candidate targets within the Plasmodium falciparum genome.
• Filtered down to 540 proteins with strong essentiality evidence and no clinical trial inhibitors.
• Prioritized 67 high-value targets for further antimalarial drug development.

Conclusions:

• A systematic, genome-wide approach can effectively identify and prioritize novel drug targets for malaria.
• The study provides a valuable data resource and a framework applicable to other pathogenic diseases.
• This work significantly advances the pipeline for discovering new antimalarial small molecule inhibitors.